Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

PublicNASDAQ:AMRS
Date10/2010
Raised
Post IPO Valuation

General Information

Websiteamyrisbiotech.com
Twitter@Amyris
CategoryCleanTech
Phone(510) 450-0761
Employees
Founded2003
DescriptionRenewable Fuels

Offices

Emeryville, USA
5885 Hollis Street, Suite 100
Emeryville, CA, 94608
USA

People

CFO
President & CEO
President
President, Research & Development
Vice President, Global Manufacturing & Process Development
board member
Board Member & Directors
board of directors
Show All People

Acquisitions

Funding

TOTAL $417M
FUNDING TOTAL $313M
Series A, 10/2006
Khosla Ventures
Kleiner Perkins Caufield & Byers
TPG Growth
$20M
Series B, 9/2007
DAG Ventures
Khosla Ventures
Kleiner Perkins Caufield & Byers
TPG Growth
$70M
Venture Round, 2/2008
$2.36M
Series B, 8/2008
DAG Ventures
Khosla Ventures
Kleiner Perkins Caufield & Byers
TPG Growth
$21M
Series C, 10/2009
Kleiner Perkins Caufield & Byers
Khosla Ventures
TPG Growth
Votorantim Novos Negocios
$41.8M
Grant, 12/2009
$24.3M
Series D, 7/2010
Temasek Holdings
$133M
POST IPO FUNDING TOTAL $104M
Post IPO Equity, 10/2010
$13.8M
Post IPO Equity, 10/2011
$7M
Post IPO Equity, 2/2012
$83.7M

Tags

Amyris Biotechnologies

Amyris Biotechnologies creates renewable products, focusing on fuels and chemicals. The company plans to enter the market by 2011.

The company is developing renewable fuels that reduce lifecycle (GHG) emissions 80%. The fuel source is special in that it is compatible with current gasoline engines, and can be distributed with existing petroleum infrastructure.

Amyris is also developing semi-synthetic artemisinin, a key ingredient in first-line malaria treatments, in hopes of creating a complementary source of non-seasonal, high-quality, affordable artemisinin. This source would supplement the current botanical supply, offering millions of people infected with malaria the chance to gain consistent and reliable access to lower-cost, life-saving Artemisinin-based Combination Therapies (ACTs).

Lastly, Amyris produces environmentally friendly chemicals for a variety of consumer products and industrial applications currently dependent on petrochemical components.

Recent Milestones

Videos

Screenshots

Amyris Biotechnologies screenshot
Above: Amyris Biotechnologies Screenshot -- #1
Uploaded: 8/9/13

Stock Price

Sources

  1. Amyris Acquires Draths (chemweek.com) [edit]
  2. Amyris gets $20M from high-profile investors to find alternative fuel (venturebeat.com) [edit]
  3. Amyris Announces $70 Million Series B Round (amyris.com) [edit]
  4. SEC (sec.gov) [edit]
  5. Amyris Picks Up Another $21M For Synthetic Bio (earth2tech.com) [edit]
  6. Amyris Closes in on $60M Round for Synthetic Diesel (earth2tech.com) [edit]
  7. SEC Filing Via Liquid Scenarios Search2Model (liquidscenarios.com) [edit]
  8. SEC (sec.gov) [edit]
  9. SEC (sec.gov) [edit]
  10. SEC (sec.gov) [edit]
  11. Amyris Secures $83.7 Million in Additional Financing (businesswire.com) [edit]
  12. Amyris Enters Into Multi-Products Collaboration and Off-Take Agreements with The Procter and Gamble Company (amyrisbiotech.com) [edit]
    Amyris Signs Agreement for up to $60 Million in Funding from Temasek (amyris.com) [edit]
Edit This Page
Last Edited 3/10/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

TechCrunch Posts TechCrunch Logo Small Picture

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy